Dr Lal PathLabs Share Price Jumps 7%, Hits 52-Week High After Q1 Results; Kotak Neo Research Raises Fair Value to ₹2,030

Dr Lal PathLabs share price rose as much as 7.79% to a fresh 52-week high of ₹1,893.65 on Monday. At 9:30 am, the stock was trading 7.24% higher at ₹1,883.80, while the BSE Sensex was up 0.78% at around 76,654.

The rally came after the diagnostics chain reported robust Q1 FY27 earnings and Kotak Neo Research reiterated its Buy rating while raising its fair value on the stock.

Dr Lal PathLabs Q1 FY2027 Results

Dr Lal PathLabs reported a consolidated net profit of ₹170 crore for the April-June quarter, up 28.8% from ₹132 crore in the corresponding period last year.

Revenue from operations increased 19.1% to ₹798 crore, compared with ₹670 crore a year ago.

Operating performance also strengthened during the quarter. EBITDA rose 28.7% to ₹248 crore from ₹192 crore in Q1 FY26, while the EBITDA margin expanded to 31% from 28.7% in the year-ago period.

The board declared an interim dividend of ₹5 per equity share for FY27 and fixed July 30, 2026, as the record date to determine eligible shareholders. The dividend will be paid within 30 days of its declaration.

Dr Lal PathLabs Q1 FY27 Results: Kotak Neo Research View

Kotak Neo Research said Dr Lal PathLabs delivered a strong quarter, supported by healthy growth in test volumes and higher realisation per test.

Patient volumes increased around 8% year-on-year, while sample volumes grew about 11%. Realisation per test improved roughly 8%, aided by price revisions under CGHS and ECHS and a richer mix of specialty tests.

The research house expects the company to deliver FY27 revenue growth at the higher end of its earlier mid-teens guidance, supported by sustained migration from unorganised to organised diagnostic players and improving performance at Suburban Diagnostics. It also noted that Dr Lal PathLabs has incorporated a wholly owned subsidiary in Dubai to expand its international presence beyond Nepal and Bangladesh.

Factoring in the stronger outlook, Kotak Neo Research now estimates EBITDA and adjusted earnings per share (EPS) to grow at a compound annual growth rate (CAGR) of around 16% and 15%, respectively, over FY26-FY29.

The firm retained its Buy rating on the stock and raised its fair value to ₹2,030, citing healthy volume growth, calibrated network expansion, improving contribution from Suburban Diagnostics and the company's strong brand positioning.

Kotak, however, said continued competition from organised diagnostic chains could limit a sharper acceleration in volume growth.

Dr Lal PathLabs Share Price Today

At 9:30 am, Dr Lal PathLabs shares were trading 7.24% higher at ₹1,883.80, outperforming the broader market after the company reported strong quarterly earnings, announced an interim dividend and received a higher fair value from Kotak Neo Research.

Also Read - IPOs This Week: Manipal Health, Juniper Green Energy, MV Electrosystems Among 3 Mainboard Issues Opening For Subscription